Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...

Equities research analysts at Wedbush dropped their FY2024 EPS estimates for Biogen in a research report issued on Thursday, ...

Stock analysts at Wedbush lowered their Q4 2024 earnings estimates for Biogen in a research report issued on Thursday, January 23rd. Wedbush analyst L. Chico now forecasts that the biotechnology ...

Biogen and AbbVie have announced the voluntary ... This includes those who experience highly active relapsing MS despite having undergone a full and adequate course of treatment with at least ...

Some neurologists have even started talking about the possibility that the drugs could not only slow down progression of MS, but even potentially offer a functional cure. Biogen licensed rights to ...

The incidence of mental illness was higher among women with MS during both the prenatal period (incidence ratio [IR] 1.26, 95 ...

Ozanimod▼ is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active ...

Court cites lack of inventiveness and failure to meet reproducibility standards | Decision part of broader international ...

Biogen Pharmachem Industries Ltd was formerly incorporated as ... appointment of Mr. Aman Patel as Director of the Company.5.) To consider the resignation of Ms. Komal Chauhan from directorship of the ...

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on a range of strategic options. However, the company's board of directors ...

Jan 27 (Reuters) - Sage Therapeutics (SAGE.O), opens new tab said on Monday that its board has unanimously rejected Biogen’s (BIIB.O), opens new tab $469 million offer, stating it "significantly ...